Medicines labeled for the same conditions
Alternatives to cilastatin and imipenem
22 other medicines are given the same way (intravenous) and in the same FDA class as cilastatin and imipenem or labeled mainly for the same use (bacterial infections); 1 is in its class, renal dehydropeptidase inhibitors: meropenem and vaborbactam; the others include 5 cephalosporin antibacterials, 2 beta lactamase inhibitors and 2 fluoroquinolone antibacterials (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as cilastatin and imipenem?
Bacterial infections lists all 51 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Cilastatin and imipenemrenal dehydropeptidase inhibitor | this medicine | 2 labelers | n/a | No | A presentation being discontinued |
| Meropenem and vaborbactampenem antibacterial · same class | Urinary tract infections | none listed | n/a | No | No current entry |
| Vancomycinglycopeptide antibacterial | Bacterial infections | 21 labelers | $2.31 per vial 500 mg vial | No | A presentation being discontinued |
| Piperacillin and tazobactambeta lactamase inhibitor | Bacterial infections | 15 labelers | $3.49 per vial 3.375 g vial | No | A presentation being discontinued |
| Levofloxacinfluoroquinolone antibacterial | Bacterial infections, Urinary tract infections | 8 labelers | n/a | Yes | No current entry |
| Clindamycinlincosamide antibacterial | Bacterial infections | 6 labelers | n/a | Yes | In shortage |
| Ampicillinpenicillin-class antibacterial | Bacterial infections, Urinary tract infections | 11 labelers | n/a | No | A presentation being discontinued |
| Linezolidoxazolidinone antibacterial | Bacterial infections | 9 labelers | n/a | No | No current entry |
| Cefoxitincephalosporin antibacterial | Bacterial infections, Urinary tract infections | 5 labelers | n/a | No | No current entry |
| Ceftriaxonecephalosporin antibacterial | Bacterial infections, Urinary tract infections | 7 labelers | $1.44 per vial 1 g vial | No | No current entry |
| Ampicillin and sulbactambeta lactamase inhibitor | Bacterial infections | 7 labelers | n/a | No | No current entry |
| Azithromycinmacrolide antimicrobial | Bacterial infections | 7 labelers | n/a | No | A presentation being discontinued |
| Metronidazolenitroimidazole antimicrobial | Bacterial infections | 7 labelers | n/a | Yes | In shortage |
| Tobramycinaminoglycoside antibacterial | Bacterial infections, Urinary tract infections | 7 labelers | $0.832 per mL 80 mg/2 mL vial | No | A presentation being discontinued |
| Penicillin gpenicillin-class antibacterial | Bacterial infections | 6 labelers | n/a | No | No current entry |
| Cefuroximecephalosporin antibacterial | Bacterial infections, Urinary tract infections | 2 labelers | n/a | No | No current entry |
| Tigecyclinetetracycline-class antibacterial | Bacterial infections | 4 labelers | n/a | Yes | No current entry |
| Sulfamethoxazole and trimethoprimsulfonamide antimicrobial | Bacterial infections, Urinary tract infections | 2 labelers | n/a | No | No current entry |
| Ceftazidimecephalosporin antibacterial | Bacterial infections | 3 labelers | $3.70 per vial 1 g vial | No | A presentation being discontinued |
| Gentamicinaminoglycoside antibacterial | Bacterial infections | 1 labeler | $1.30 per mL 80 mg/2 mL vial | No | No current entry |
| Erythromycinmacrolide | Bacterial infections | 3 labelers | n/a | No | No current entry |
| Moxifloxacinfluoroquinolone antibacterial | Bacterial infections | 1 labeler | n/a | Yes | A presentation being discontinued |
| Cefotaximecephalosporin antibacterial | Bacterial infections | 1 labeler | n/a | No | In shortage |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Cilastatin and imipenem: the full record
- label, generics, price, shortages, recalls